Inhibrx (NASDAQ:INBX – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Inhibrx to post earnings of ($2.88) per share for the quarter.
Inhibrx Stock Down 1.1 %
Inhibrx stock opened at $12.35 on Wednesday. The stock’s 50 day simple moving average is $13.73 and its two-hundred day simple moving average is $14.60. Inhibrx has a fifty-two week low of $10.80 and a fifty-two week high of $18.95.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
- Five stocks we like better than Inhibrx
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- What is the Dow Jones Industrial Average (DJIA)?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Canada Bond Market Holiday: How to Invest and Trade
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
